IL1A and lung carcinoma: Moreover, we found that anakinra therapy significantly delays lung cancer progression in Il1a-/- recipient mice with old donor bone marrow (Fig. 4K), indicating that the anti-tumoral potency of anakinra is determined by the disruption of IL-1α signaling from immunological sources, which we specified is largely contributed by lung MPs in the local TME.